Drugs / HCP1803
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03897868 | Mar 2019 → Feb 2020 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06438172 | Mar → Dec 2024 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06438172 ↗ |